Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.24.1.1.u2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Balance at the beginning at Jun. 30, 2022 $ 2,882 $ 0 $ 152,454 $ (148,327) $ (1,245)
Balance at the beginning (In shares) at Jun. 30, 2022   480,688      
Issuance of common stock, pre-funded warrants, and Series 2/common warrants sold for cash, net of offering costs 16,015 $ 0 16,015    
Issuance of common stock, pre-funded warrants, and Series 2/common warrants sold for cash, net of offering costs, Shares   1,037,520      
Share-based compensation 302   302    
Foreign currency translation gain (loss) 507       507
Net loss (5,093)     (5,093)  
Balance at end at Sep. 30, 2022 14,613 $ 0 168,771 (153,420) (738)
Balance at end (In shares) at Sep. 30, 2022   1,518,208      
Balance at the beginning at Jun. 30, 2022 2,882 $ 0 152,454 (148,327) (1,245)
Balance at the beginning (In shares) at Jun. 30, 2022   480,688      
Foreign currency translation gain (loss) 392        
Net loss (14,901)        
Balance at end at Mar. 31, 2023 4,713 $ 0 168,794 (163,228) (853)
Balance at end (In shares) at Mar. 31, 2023   1,645,951      
Balance at the beginning at Sep. 30, 2022 14,613 $ 0 168,771 (153,420) (738)
Balance at the beginning (In shares) at Sep. 30, 2022   1,518,208      
Exercise of pre-funded warrants, Shares   127,743      
Share-based compensation (48)   (48)    
Foreign currency translation gain (loss) (160)       (160)
Net loss (5,411)     (5,411)  
Balance at end at Dec. 31, 2022 8,994 $ 0 168,723 (158,831) (898)
Balance at end (In shares) at Dec. 31, 2022   1,645,951      
Share-based compensation 71   71    
Foreign currency translation gain (loss) 45       45
Net loss (4,397)     (4,397)  
Balance at end at Mar. 31, 2023 4,713 $ 0 168,794 (163,228) (853)
Balance at end (In shares) at Mar. 31, 2023   1,645,951      
Balance at the beginning at Jun. 30, 2023 202 $ 0 168,921 (167,889) (830)
Balance at the beginning (In shares) at Jun. 30, 2023   1,671,485      
Issuance of common stock, pre-funded warrants, and Series 2/common warrants sold for cash, net of offering costs 27,919 $ 0 27,919 0 0
Issuance of common stock, pre-funded warrants, and Series 2/common warrants sold for cash, net of offering costs, Shares   875,949      
Share-based compensation 91   91    
Foreign currency translation gain (loss) 50       50
Net loss (5,954)     (5,954)  
Balance at end at Sep. 30, 2023 22,308 $ 0 196,931 (173,843) (780)
Balance at end (In shares) at Sep. 30, 2023   2,547,434      
Balance at the beginning at Jun. 30, 2023 202 $ 0 168,921 (167,889) (830)
Balance at the beginning (In shares) at Jun. 30, 2023   1,671,485      
Foreign currency translation gain (loss) (5)        
Net loss (17,031)        
Balance at end at Mar. 31, 2024 11,500 $ 0 197,255 (184,920) (835)
Balance at end (In shares) at Mar. 31, 2024   2,724,794      
Balance at the beginning at Sep. 30, 2023 22,308 $ 0 196,931 (173,843) (780)
Balance at the beginning (In shares) at Sep. 30, 2023   2,547,434      
Exercise of pre-funded warrants, Shares   25,000      
Share-based compensation 93   93    
Foreign currency translation gain (loss) (172)       (172)
Net loss (6,798)     (6,798)  
Exercise of Series 2 warrants (In shares)   20,000      
Exercise of Series 2 warrants 39   39    
Balance at end at Dec. 31, 2023 15,470 $ 0 197,063 (180,641) (952)
Balance at end (In shares) at Dec. 31, 2023   2,592,434      
Exercise of pre-funded warrants, Shares   132,360      
Share-based compensation 192   192    
Foreign currency translation gain (loss) 117       117
Net loss (4,279)     (4,279)  
Balance at end at Mar. 31, 2024 $ 11,500 $ 0 $ 197,255 $ (184,920) $ (835)
Balance at end (In shares) at Mar. 31, 2024   2,724,794